Illumina reported third-quarter revenue of $1.13 billion, a 4.2% increase from the prior year period, driven by healthy clinical demand and robust NovaSeq X placements. GAAP diluted earnings per share were $1.43, while non-GAAP diluted EPS excluding tariff refunds was $1.44. The company raised its full-year revenue guidance to $4.64-$4.66 billion from the previous range of $4.60-$4.64 billion and increased its non-GAAP operating margin expectation to 23.6%. Illumina operates in the life sciences industry, providing DNA sequencing and array-based technologies for research, clinical, and applied markets.
